Cargando…

Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction

Chronic heart failure is a common clinical condition characterized by persistent excessive sympathetic nervous system activation. The derangement of the sympathetic activity has relevant implications for disease progression and patient survival. Aiming to positively impact patient outcome, autonomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gronda, Edoardo, Francis, Darrel, Zannad, Faiez, Hamm, Christian, Brugada, Josep, Vanoli, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555968/ https://www.ncbi.nlm.nih.gov/pubmed/28737621 http://dx.doi.org/10.2459/JCM.0000000000000544

Ejemplares similares

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
por: Coats, Andrew J.S., et al.
Publicado: (2022)

Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review
por: Molina‐Linde, Juan Máximo, et al.
Publicado: (2023)

Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report
por: Dell’Oro, Raffaella, et al.
Publicado: (2017)

Updates on Baroreflex Activation Therapy and Vagus Nerve Stimulation for Treatment of Heart Failure With Reduced Ejection Fraction
por: Babar, Natasha, et al.
Publicado: (2022)

Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy
por: Nottebohm, Pia I., et al.
Publicado: (2022)

Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience
por: Blanco, Carola, et al.
Publicado: (2023)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review
por: Schmidt, Rodrigo, et al.
Publicado: (2020)

Oscillatory Pattern of Sympathetic Nerve Bursts Is Associated With Baroreflex Function in Heart Failure Patients With Reduced Ejection Fraction
por: Toschi-Dias, Edgar, et al.
Publicado: (2021)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study
por: Gronda, Edoardo, et al.
Publicado: (2014)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure
por: Lindenfeld, JoAnn, et al.
Publicado: (2021)

Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
por: Neves, João Sérgio, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results
por: Piayda, Kerstin, et al.
Publicado: (2022)

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Lam, Carolyn S P, et al.
Publicado: (2021)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022)

Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
por: Vishram-Nielsen, Julie K. K., et al.
Publicado: (2022)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score
por: Huttin, Olivier, et al.
Publicado: (2021)

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nh7evg6vc0ahknpllbgncf0hu5